Goingtomeet.com Press

Conference Dates: Sept 26 – 27, 2011
Venue: Radisson BLU Brussels, Belgium

PK/PD Modeling is quickly becoming a timely and cost efficient means of assessing the activity of a compound on the target.

The benefits of an effective PK/PD modeling setup include more informed decision making at earlier stages which can lead to increased understanding of a compounds safety, particularly in special populations such as pediatric/geriatric and also populations who would normally be excluded from clinical studies. Recently several new PK/PD software platforms have been released and these will also improve the ability of PK/PD scientists to bring more accurate predictions and understanding of the work they perform. This training course is aimed at more junior PK/PD scientists and also those who wish to be able to assess the new software’s ability to perform as they desire.

The course will introduce participants to the more advanced concepts, methodologies and applications of Pharmacokinetic and Pharmacodynamic modeling and simulation and quickly progress through several case studies using real, but hidden datasets which will enable them to gain a perspective of the advantages that a well-run PK/PD program can deliver to the entire development process.

Agenda request
To request the full agenda please follow the link:
http://www.nextlevelpharma.com/events/request_agenda/advanced_applications_in_pk_pd_modeling

For Booking Information contact:
Erika Vavrovicova

Tel: +421 232 660 382
Fax: +421 2 3301 0331
Email: erika@nextlevelpharma.com
Visit: www.nextlevelpharma.com

-Specialist training-

Non-Compartmental, Compartmental and Population Analysis using Phoenix Winnonlin and Phoenix NLME

Conference Dates: July25-26^th& September 26-27th, 2011

Venue: Brussels,Belgium

PK/PD Modeling is quickly becoming a timely and cost efficient means of assessing the activity of a compound on the target. The benefits of an effective PK/PD modeling setup include more informed decision making at earlier stages which can lead to increased understanding of a compounds safety, particularly in special populations such as pediatric/geriatric and also populations who would normally be excluded from clinical studies. The course will introduce participants to the basic notions of Pharmacokinetic and Pharmacodynamic modeling and simulation and quickly progress through several case studies using real, but hidden data sets which will enable them to gain a perspective of the advantages that a well-run PK/PD program can deliver to the entire development process.

Please note that the course is a 1.5 day training, with the option of two sets of dates for your flexibility. It is not a series of 2 training sessions.

What Participants will Learn:

• The basics of Non Compartmental Analysis and how practically perform a Non Compartmental Analysis using Phoenix Winnonlin.
• How to translate biological processes into a mathematical framework (compartment analysis, turnover processes, etc.) and how to use built in libraries stored in Phoenix Winnonlin.
• How to perform Population data analysis using response data from real clinical trials and how to perform a population analysis using Phoenix Non Linear mixed effect modeling engine.
• How to optimally use the results of these analyses to guide optimal future clinical trial design. They will learn how to perform simulation using the Phoenix simulation engine.
• They will possess new tools to both either increase the probability of success in having the drug approved or making earlier no go decision for drug that would appear to be not enough efficacious or not enough safe. Many case studies will be discussed where it will be shown how modeling and simulation tools helped during the entire drug development process to prove drug efficacy and prevent false positive conclusions (The drug is working when in fact it does not).

Target audience

PK/PD & Simulation scientists interested in getting basic knowledge of modeling and simulations, working in the field of clinical pharmacology or related fields who may be Junior or those who are looking to gain an increased understanding of PK/PD theory and practicalities, also for those looking to assess the suitability of new PK/PD software platforms.

Our Trainer: Serge Guzy

With 20 years of experience with modeling and simulation, Serge Guzy is currently President, CEO of POP-PHARM, a consulting and software Development Company www.poppharm.com.

He established new methods for statistical population approaches in drug development, based on Monte Carlo simulation algorithms.

The resulting MC-PEM methodology and Population software development made him internationally recognized. These new tools have already been well utilized in drug development, from the early stage of drug discovery and lead selection programs as a useful tool to guide drug design goals and inform teams for better decision making, as well as in clinical development as a tool for guiding optimally new trial designs.

Agenda request

To request the full agenda please follow the link:

http://www.nextlevelpharma.com/events/request_agenda/introduction_to_pk_pd_modeling

For Booking Information contact:

Erika Vavrovicova

Tel: +421 232 660 382

Fax: +421 2 3301 0331
Email: erika@nextlevelpharma.com

Visit: www.nextlevelpharma.com

Dresden/Germany, 31 August 2009 – ITI GmbH, international leader in virtual system engineering, today announces its debut in Great Britain. The foundation of ITI Northern Europe Limited enables the company to extend its presence on international markets and to provide its customers in Northern Europe with class-leading levels of service support, sales and customer-orientation. ITI also announces the expansion of its Headquarters in Dresden/Germany; software development will be continuously strengthened. Counter the general economic trend, the company performed well in the first half of the year and is financially set for further expansion with sales running stable and an increasing global demand for ITI simulation solutions.

For many years with more than 25 selected distributors on three continents, ITI has been cooperating with a successful network of stand-alone, state-of-the-art partners dedicated to the sales and service of SimulationX, the standard multi-domain software for system simulation. The establishment of the UK facility in Milton Keynes is a debut in ITI history thus tightening its international market position. The new subsidiary has already started operation and acts independently in local sales, marketing, and human resources development. Simulation solutions are provided and supported for SimulationX customers in the United Kingdom, Ireland, Belgium, Netherlands, Luxembourg, Norway, Denmark, Sweden, and Finland. Chris Litchfield becomes Business and Sales Manager for Northern Europe and will be supported by Emmanuel Domingues, Technical Manager. Each of them brings more than eight years experience in delivering system simulation solutions to a wide range of industries.

We want to advance our commitment to ITI customers in Northern Europe by providing the world’s highest level of satisfaction in service support and sales of SimulationX thus implementing true innovations together. Our aim is to become a key player on the European CAE market within the next two years, said Jens O. Schindler, ITI Managing Director, about the aims of the new facility. “In the past years ITI strengthened its position as a leader in virtual system engineering and became an internationally-demanded engineering partner, adds Dr. Andreas Uhlig, ITI Managing Director, and further explains: “With highly-qualified people and financial strength we are ready for new investments to expand our business. The establishment of the subsidiary is a milestone in ITI’s company history.

About ITI

For more than 18 years ITI has been one of the internationally leading companies for the virtual system engineering. The software SimulationX is applied by engineers and scientists at more than 600 well-known companies such as Audi, BMW, Daimler, Volkswagen, Continental, Schaeffler, Siemens, Demag, Husky, Nikon, Mitsubishi and Liebherr. SimulationX is also widely used in academics and research world-wide. Main fields of application are power engineering, Power transmission, fluid power, mechanical engineering, power generation and automotive. Apart from this ITI supports its clients in the field of research and development of high-technology with engineering and consulting services. In the field of real-time and HiL test-system applications ITI provides turnkey projects and references for various companies including CNH, Putzmeister or Hoerbiger. Further information on www.iti.de.

About SimulationX

SimulationX – The Driving Force in System Simulation determines the level of modeling, simulating and optimizing complex technical systems. The software models the interaction of components from a multitude of domains including their mutual interaction and feedback on one platform. This significantly distinguishes SimulationX from any other kind of CAE software (FEM, CFD, MBS). SimulationX is the standard in software for evaluation of the interaction of all components in technical systems. It is the universal CAE tool for modeling, simulating and analyzing physical effects – with ready-to-use model libraries for 1D mechanics, 3D multi-body systems, power transmission, hydraulics, pneumatics, thermodynamics, electrics, electrical drives, magnetic as well as controls – post-processing included. SimulationX fully supports Modelica® language and offers a wide range of open, comprehensive CAx-interfaces. Further information on www.simulationx.com.

If reprinted please provide us with a copy as reference.

Contact
ITI Headquarters
Denise Börner
Manager Marketing/Public Relations
Webergasse 1
01067 Dresden
Germany
Tel. +49 (0) 351/260 50 0
Fax +49 (0) 351/260 50 155
Email boerner@iti.de

How interested are you to gain preferential market access via innovative payer agreements?

NextLevel Pharma is organising the only meeting looking at risk-sharing and value-based pricing and reimbursement schemes.

Achieving preferential market-access through innovative agreements with payers

( Brussels, Belgium, 23rd- 24th April, 2009)

This will be an ideal opportunity to understand and learn from the experiences and opinions of other pharma and medical devices companies, HTA agencies, payers and keystakeholders and benchmark globally.

Find your reasons to Attend:

• Understand what are the most up to date, innovative agreement solutions and future trends in different countries globally
• Learn how drug effectiveness, value and safety are being demonstrated in deferent regions.
• Benchmark, network and co-operate with policy makers and key, influential figures. Get the best and most focused picture of risk-sharing and value-based pricing models today.
• Hear the perspectives of all stakeholder groups: Ministries of Health, HTA Agencies, Insurers, Doctors, Patients and Patient Groups, Health Economists and the Pharmaceutical Industry.
• Discover how payers are evaluating a range of complex pricing and reimbursement agreements.
• Understand what patients want and what they define as a quality treatment, that enhances their lives.
• Find out if risk-sharing and value-based pricing schemes can help pharma and medical device manufactures achieve preferential
• market access and a competitive advantage.
• Understand the best ways to comunicate value with stakeholders and achieve maximum patient and market access.

Speakers include:

 GlaxoSmithKline, UK- Director Global Health Outcomes, Oncology

 Novartis, Switzerland- Global Brand Pricing & Reimbursement Director

Astellas, UK- Vice President, Medical Affairs & Health Economics Europe

 Medtronic- Director, Reimbursement and Health Economics, Central and Eastern Europe, Greece and Israel

 Indiana Office of Medicaid Planning and Policy, USA- Director, Health Quality, Policy Research and Strategic Planning

OHE, UK- Director of the Office of Health Economics

NHS Innovations London- Head of Health Outcomes Unit

Tufts Center for the Study of Drug Development, USA- Associate Director

Luiss University & Business School, Rome- Healthcare and Pharmaceutical Economics and Polices

 Oncology Center Antwerp- Director

 Tufts Center for the Study of Drug Development, USA- Associate Director

 Luiss University & Business School, Rome- Healthcare and Pharmaceutical Economics and Polices

 Oncology Center Antwerp- Director

Together, they will deliver knowledge, expertise, insights, opinions, facts and data that can add strategic intelligence and real-value to your business.

Agenda Request:
To request the agenda, registration form and to learn more about this event, please follow the link:

http://www.nextlevelpharma.com/events/request_agenda/22
In case you have any problems with link, please contact me directly and I will send the agenda to you immediately.

CO-LOCATED EVENT

MARKET ACCESS STRATEGIES FOR PERSONALISED MEDICINES

AND COMPANION DIAGNOSTICS

BUILDING  VALUE-PROPOSITION AND BUSINESS MODEL TO REALISE THE FULL COMMERCIAL POTENTIAL OF PERSONALISED HEALTHCARE

(Brussels, April 21-22nd April)

  Contact:

Erika Vavrovicova

NextLevel Pharma

ph: +421 2 3266 2621

fax: +421 2 3266 0395

erika@nextlevelpharma.com  

Exploring the commercial viability of therapies for genetically-defined markets

(Brussels, Belgium, 21st-22nd April, 2009) 

How important is it for you to develop a deeper understanding of how to build a profitable business model in personalised medicine?

NextLevel Pharma is organising the only meeting looking at how to realise the full commercial potential of personalised healthcare  and how to achieve pricing and reimbursement for such drugs and diagnostics. This is not another scientific event.

Find your reasons to Attend:

• Gain a complete understanding and overview of the economic and business realities and potential of personalised healthcare today and in the future.
• Find out if blockbuster strategy is alive or dead in the eyes of market, payers and health technology assessors.
• Determine the real market value of personalised medicines and companion diagnostics in terms of how much payers are willing to invest in such innovation.
• Understand the pricing and reimbursement strategies of pharma and diagnostics companies to gain market access to their innovative products in this field.
• Understand how to design a commercially-viable business model for both drugs and companion diagnostics.

Speakers include:

Tufts Center for the Study of Drug Development, USA- Associate Director

University of California at Berkley, USA- Chief Correspondent for National Public Radio Talk’s “Biotech Nation” Director, The Center for Life Science Policy

Personalized Medicine Coalition, USA- Executive Director

Bayer- AG- Governmental Affairs Manager

Astrazeneca, USA – Global Director, Business Development, Personalized Medicine (invited)

DNA-Guide, Sweden- CEO

NHS Innovations London- Head of Health Outcomes Unit

Diaceutics, UK- CEO

Hogan & Hartson LLP, Belgium- Partner

Vision Healthcare Consultancy Ltd, UK- CEO

RTI Health Solutions- Vice President Global Pricing & Reimbursement Practice

..and many more!!! 

Together, they will deliver knowledge, expertise, insights, opinions, facts and data that can add strategic intelligence and real-value to your business.

Agenda Request:
To request the agenda, registration form and to learn more about this event, please follow the link:

http://www.nextlevelpharma.com/events/request_agenda/19 
In case you have any problems with link, please contact me directly and I will send the agenda to you immediately. 

CO-LOCATED EVENT

RISK-SHARING & VALUE-BASED

PRICING & REIMBURSEMENT SCHEMES

Achieving preferential market-access through innovative agreements with payers

(Brussels, 23rd-24th April, 2009)

Contact:

Erika Vavrovicova

NextLevel Pharma

ph: +421 2 3266 2621

fax: +421 2 3266 0395

erika@nextlevelpharma.com